Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer

The implementation of cancer immunotherapeutics for solid tumors including lung cancers has improved clinical outcomes in a small percentage of patients. However, the majority of patients show little to no response or acquire resistance during treatment with checkpoint inhibitors delivered as a mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Konen, Jessica M., Rodriguez, B. Leticia, Fradette, Jared J., Gibson, Laura, Davis, Denali, Minelli, Rosalba, Peoples, Michael D., Kovacs, Jeffrey, Carugo, Alessandro, Bristow, Christopher, Heffernan, Timothy, Gibbons, Don L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521201/
https://www.ncbi.nlm.nih.gov/pubmed/30986992
http://dx.doi.org/10.3390/cancers11040462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521201/
https://www.ncbi.nlm.nih.gov/pubmed/30986992
http://dx.doi.org/10.3390/cancers11040462

Ejemplares similares